Medivir Financial Statement 1 Jan-31 Dec 2003

MEDIVIR FINANCIAL STATEMENT 1 January - 31 December 2003 · MIV-310 was outlicensed to Boehringer Ingelheim in July in a global licensing agreement with a total contract value of € 122 m. · MIV-210 was outlicensed in May to GlaxoSmithKline as part of a global licensing agreement with a total contract value of € 86 m of which Medivir received € 6 m at the time of signing the agreement. · In November, Roche and Medivir entered into two agreements within the field of virology. Within the HIV field, the companies restructured the existing collaborative agreement for MV026048 and, for hepatitis C, they entered into a new research partnership agreement. · In November, Medivir and Hengrui signed a research partnership agreement to develop drugs to combat chronic obstructive pulmonary disease (COPD). · In July, Medivir entered into a licensing agreement for MIV-150 with the Population Council. · In November, Medivir and Peptimmune Inc. were granted an EU patent for the use of Cathepsin S-inhibitor in therapeutic formulations for alleviating immune reactions. · Major progress has been made in the Cathepsin projects. · On 1 July, Medivir divested its subsidiary CCS for SEK 210 m. · Lars Adlersson entered the position as CEO and President on 1 March. · Net sales amounted to SEK 149.0 m inclusive CCS half-year (256.3 m inclusive CCS whole-year). Profit after tax were SEK -40.3 m (SEK -59.8 m), earnings per share amounted to SEK -4.69 (SEK -7.09). FOR FURTHER INFORMATION, PLEASE CONTACT Rein Piir, CFO and VP IR, +46 (0)8 5468 3123 or +46 (0)708 537292 ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/02/17/20040217BIT00470/wkr0001.doc The full report http://www.waymaker.net/bitonline/2004/02/17/20040217BIT00470/wkr0002.pdf The full report

About Us

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Subscribe